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Welcome to Fusion
Dear GW Community and fellow research enthusiasts,
As part of our commitment to fostering student
interest in research, the William Beaumont Medical
Research Honors Society at The George Washington
University School of Medicine and Health Sciences
is proud to introduce the 2014 edition of Fusion — a
student-run research journal that serves as a forum for
students to share their research experiences with the
GW medical community.
This year’s edition focuses on the theme of putting
basic science research into clinical practice. Medicine
is an incredibly dynamic and rapidly evolving field. At
the same time, basic science is identifying new molecular pathways, genetic polymorphisms in disease, and
targeted pharmaceutical therapies at an impressive
rate. While these developments are aimed at advancing
the medical field, the integration of these innovations
into clinical practice also poses a unique challenge for
today’s healthcare professionals.
Never before has the collaboration and coordination of researchers and health care providers been
more important. As future health care professionals
it is imperative that we seek to continue to integrate
these dynamic aspects into our own practice. However,
learning these skills most often requires us to immerse
ourselves in enriching experiences outside the classroom, and it is these endeavors that Fusion highlights.
This publication features a “fusion” of clinical, basic
science and public health research, reflecting the

experiences of a number of enthusiastic and dedicated
members of the GW SMHS student body. We hope
that as you enjoy reading the following articles you are
inspired to seek opportunities that will help strengthen
your own skills as future healthcare professionals.
Lastly, we would like to thank all of our authors and
artists who help to make Fusion a great success each
year. We also extend our many thanks to the Office of
the Deans for their generous support, and to the staff at
SMHS Communications and Marketing for helping to
make Fusion a reality.
Sincerely,
Your editors:
Ritesh Agnihothri
Caitrin Coffey
Cate Haring
Navid Hejazifar
Joshua Jabaut
Charmaine Jamias
John McLaughlin
Brent Ozaki
Justin Palanci
Brian Park
Monica Passi
Rajeev Samtani
Jeffery Shu-Chieh Yu
Kelly Zhang

The brain is the most complicated
organ in the human body. Anatomical
and physiological circuits provide
us with the ability to communicate,
experience emotion, learn, create
memories, and much more.
The cover image was created
by second-yea r medica l student
Cate Haring, while she was conducting neuroscience research at
Children’s National Health System
in Washington, D.C. Over the course
of her research Haring was struck by

the beauty, complexity, and mystery of
neural circuits involved in both health
and disease. Novel imaging techniques
and molecular diagnostic studies are
beginning to shed light on the pathogenesis of neurological conditions,
however there remains much to be
discovered. Haring used cherry blossoms in the cover image to represent
the beauty she found in neural circuits
and the current neuroscience research
being conducted in Washington, D.C.
Behind the acrylic painting is a representation of neurons firing.

THE GEORGE
WASHINGTON
UNIVERSITY
STEVEN KNAPP, Ph.D.
University President
JEFFREY S. AKMAN,
M.D. ’81, RESD ’85
Walter A. Bloedorn, Professor
of Administrative Medicine
Vice President for Health
Affairs and Dean of the
School of Medicine and
Health Sciences (SMHS)
VINCENT A.
CHIAPPINELLI, Ph.D.
Associate Vice Provost for
Health Affairs, Associate
Dean of SMHS, and Ralph
E. Loewy Professor and
Chair of Pharmacology and
Physiology

Editorial Board:
Ritesh Agnihothri
Caitrin Coffey
Cate Haring
Navid Hejazifar
Joshua Jabaut
Charmaine Jamias
John McLaughlin
Brent Ozaki
Justin Palanci
Brian Park
Monica Passi
Rajeev Samtani
Jeffery Shu-Chieh Yu
Kelly Zhang
Project Management
Team:
Thomas Kohout
Kristin Hubing
Laura Otto
Designer:
Michael Leong

Fusion

is a publication of the William
H. Beaumont Medica l
Research Honor Society. The
journal is published by SMHS
st udents i n col laboration
w ith the SMHS Off ice of
the Dea n a nd the Of f ice
of C om m u n ic a t ion s a nd
Marketing.

Fusion ✦ 2014

Table of Contents
LETTER

BIOMEDICAL

Serendipity and the Path to Discovery
Anthony Samuel Lamantia, Ph.D.. . . . .p. 2
CLINICAL

Identifying Directional Secretomes
of In Vitro Differentiated Normal
Primary Bronchial Epithelium
Eric Johnson, MSIII . . . . . . . . . . . . . .p. 17

Moderate Weight Loss is Sufficient to
Affect Thyroid Hormone Homeostasis
and Inhibit Its Peripheral Conversion
Ritesh Agnihothri, MSII . . . . . . . . . . . .p. 4

An Alternative Replication Pathway
Induced by Apoptosis in Cell Lines
Latently Infected with Human Herpesvirus
Jill Remick, MSIII. . . . . . . . . . . . . . . .p. 18

Retinal Ganglion Cell Layer Thickness
in Children with Vision Loss from
Optic Pathway Gliomas
Sherry Gu, MSIII . . . . . . . . . . . . . . . . .p. 6

The Search for Novel Atopic
Dermatitis Therapies: β-DefensinInducing Plant Extracts
Ryan Vesny, MSIII . . . . . . . . . . . . . . p. 20

Safety and Efficacy in Nonendoscopic
Transaxillary Breast Augmentation
Robert John Hagenberg, CPA, MSIII p. 6

Regenerative Strategies in
Bladder Outlet Obstruction
Jeffery Yu, MSIII . . . . . . . . . . . . . . . p. 21

The Prevalence of Myofascial Tender
and Trigger Points in Patients
Presenting with Cervico-Thoracic and
Lumbro-Sacral Spine Related Pain
Emily Harmon, MSIII . . . . . . . . . . . . . .p. 8
Where Should Intratesticular
Resistive Index Be Measured?
Siobhan Hartigan, M.D. ’13 . . . . . . . . .p. 9
Association Between Thromboembolic
Complications and Increased Mortality
After Pediatric Cardiac Surgery
Navid Hejazifar, MSIII . . . . . . . . . . . .p. 10
A Variant in SLC30A8 Gene is
Associated with Skeletal Muscle
Size and Damage in Young Men
Jason S. Lipof, MSII . . . . . . . . . . . . . .p. 11
Nutrition Intake in Youths
with Type I Diabetes
Lyndsay O’Brecht, MSIII, M.Sc. . . . . .p. 13
Patterns of Post-Operative Venous
Thromboembolism Prophylaxis
in Gynecologic Oncology
Andrea Winter, MSIII . . . . . . . . . . . . .p. 15
Emergency Department Physicians’
Comfort Levels with Diagnosing
and Treating Depression
Elizabeth J. Yetter, MSIII . . . . . . . . . .p. 16

REVIEWS
Underdiagnosed Pain in HIV/AIDS Patients
Bahaa Daoud, MSIII . . . . . . . . . . . . . p. 23
A Review of Neural Biochemical
Markers for Mild Traumatic Brain
Injury Characterization
Joseph A. Wong, MSIII . . . . . . . . . . .p. 24
EPIDEMIOLOGY
A Syndromic Approach to Emergency
Department Surveillance for Skin
and Soft Tissue Infections
Leah Gustafson, MSIII . . . . . . . . . . . p. 26
CASE REPORT
Iris Melanoma in Children: Current
Approach to Management
John McLaughlin, MSIII . . . . . . . . . . p. 27
MEDICAL EDUCATION
Understanding the Experience
of Mature-Age Medical Students
Compared to Traditional Medical
Students in the Clinical Setting
Mai Abdelnabi, MSIII. . . . . . . . . . . . p. 29

1

Serendipity and the Path to Discovery

Anthony-Samuel LaMantia, Ph.D.

In the 1960s and 1970s, equipped with of “first generation” tools
of molecular biology — as well as classical biochemistry and the
emerging discipline of “cell biology” — a whole generation of physicians and scientists worked side-by-side to fight a “war” on cancer.
The partnership was inspiring, and facilitated by medical education at
the time. First- and second-year medical students were taught by the
faculty members who were actually doing the research, and lectures
often included the newest data from their own or other laboratories.
This “hot off the bench” approach primed a whole generation of physicians to be ready to apply insights of basic molecular biology not only
to new diagnostic and therapeutic approaches to cancer, but also to
new infectious diseases that arose 20 years later (HIV, SARS, Ebola
virus), and the newer “genetic medicine” that crystalized following
completion of the first-draft human genome sequence in the late
1990s. This progress produced declines in mortality and morbidity
due to cancers: now diagnosis, though serious, is not a shameful
death sentence. New treatments provide multiple opportunities for
intervention, and in some cases partial or even complete (as one can
tell) cures. Neuroscientists view this nearly 60-year odyssey with
admiration and a little bit of envy — if only we could report the same
level of advance.

The achievements of neuroscience seem slower, and clinical benefits have not yet been fully realized. When
I was a student-scientist in the mid 1980s, there was a sense that a “first draft” of the rules of neuron structure,
physiological function, and behavioral output by which nervous systems operated was nearly complete. The
foundational work of the people who taught me about the nervous system — including Pasko Rakic, M.D., Ph.D.;
Patricia Goldman Rakic, Ph.D.; and Gordon Shepherd, M.D., D.Phil, at Yale University; Eric Kandel, M.D.,
and Dale Purves, M.D., at Cold Spring Harbor Laboratory; and many others — inspired me. The work we read
by then leaders in the field such as Viktor Hamburger, Ph.D., and Nobel Prize winners Paul Greengard, Ph.D.;
David Hubel, M.D.; Rita Levi Montalcini, M.D.; Erwin Neher, Ph.D.; Bert Sakmann, M.D.; Thomas Sudhof,
M.D.; and Torstein Wiesel, M.D., gave me a sense that the inpenetrable gray lump that most biologists dismissively considered the brain to be, could actually be studied using the same approaches as every other organ system.
A second wave of revolutionary developments in molecular biology and genetics in the 1990s made it possible
to consider the foundational “first draft” of how brains might work as a starting point to define molecular and
cellular mechanisms that lead to devastating and intractable brain diseases.
At that moment I was fortunate enough to begin my scientific career as an independent investigator — first at
Duke University, then at The University of North Carolina at Chapel Hill (UNC), and now at GW. I acquired a
new tool kit of molecular biological approaches, with the help of my collaborator and friend Elwood Linney and
several gifted students and post-docs. We focused on studying novel cell signaling mechanisms. We wished to
understand how neural stem cells in the very early embryonic brain receive instructions that gave them identity.
Surprisingly, the molecular mechanisms we identified were the same ones used for similar — though not identical — tasks that faces, hearts, and limbs together during early embryonic development. At this point, a truly
fortunate event occurred: an academic psychiatrist, Jeffrey Lieberman, M.D. (who is, by the way, a GW Medical
School alumnus) made me aware of a recently defined genetic disease — DiGeorge or 22q11 Deletion Syndrome,
with an incidence rate of 1/3000 live births caused craniofacial, limb, and heart malformations recognized at
birth (and, in the case of heart malformations, repaired shortly after birth to insure survival), followed by a
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Newer “genetic medicine” that
crystallized following completion of the
first-draft human genome sequence in
the late 1990s helped produce significant
declines in mortality and morbidity due
to cancer. Using those tools of molecular
biology, today’s scientists could unlock
similarly transformational discoveries in
the world of neuroscience.

remarkable increase in early onset schizophrenia in many patients, autism and mood disorders in most others.
Jeff Lieberman and I recognized that the basic biology I had done and the clinical characteristics of this disorder
likely had something to do with one another. With Jeff Lieberman’s instruction in the details of clinical brain
disorders such as schizophrenia and autism, and using the tools of molecular biology — especially the ability to
model human genetic disorders in the mouse — we defined how the genetic lesion that “causes” 22q11 Deletion
Syndrome disrupts the shared mechanisms for heart, face, limb, and brain development. We also found, to our
surprise, that this genetic disruption goes on to compromise development of neural circuits in the cerebral cortex
that are essential for specific cognitive behaviors.
The happy accident of meeting Lieberman occurred by chance during a scientific meeting (in Hawaii …
doubly lucky for me!), and resulted in my migration from Duke to UNC where Lieberman was at the time.
Jeff is now the chair of psychiatry at Columbia University, and Director of the New York State Psychiatric
Institute. His work on the efficacy of antipsychotic drugs defines clinical practice, and his ongoing work on the
biology of schizophrenia and other affective disorders is a model for translational research — he’s an inspiring
GW alumnus. My goal, as I took on the role of founding director of the GW Institute for Neuroscience, was to
facilitate many more similar “happy accidents” for GW clinicians, scientists, and students here in Foggy Bottom
(sorry, no Hawaii trips). Together, we can define a new translational research enterprise in the neuroscience of
brain diseases. Our efforts over the past four years are only now beginning to produce exciting results, but we
are well positioned to drive full speed ahead— with fellow neuroscientists throughout the country and world —
toward the seemingly bleak horizon of brain disease, and improve the outlook with new discoveries. Perhaps 60
years from now, another GW faculty member, writing another faculty letter for the Beaumont Society’s journal
Fusion, will look back on our collective efforts at GW, and throughout the scientific community, in the same way
that we now look back upon the beginning of the “war on cancer”: — an intrepid collaboration between physicians and scientists — those already trained, and those in training — that defined a path to better outcomes for
generations of patients yet to come.
— Anthony-Samuel LaMantia, Ph.D.
professor of pharmacology & physiology, and founding
director of the GW Institute for Neuroscience

LETTER
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Clinical:
Moderate Weight Loss is Sufficient to Affect
Thyroid Hormone Homeostasis and Inhibit
Its Peripheral Conversion
Ritesh
Agnihothri, MSII
ADVISORS:
Amber Courville,
Ph.D., RD2; Joyce
D. Linderman
M.S., R.N.1; Sheila
Smith R.N.1, Robert
Brychta, Ph.D.1; Alan Remaley, Ph.D.3, Kong
Y. Chen, Ph.D.1; Louis Simchowitz, M.D.1,4;
Francesco S. Celi, M.D.1

TABLE 1: Study Participants’ Characteristics and
Laboratory Data$
Non-Overweight Group
Parameter

Diabetes, Endocrinology, and Obesity Branch,
NIDDK, NIH; 2Nutrition Department, Clinical
Center, NIH; 3Department of Laboratory
Medicine, Clinical Center, NIH; 4Office of the
Director, NIDDK, NIH. Bethesda, MD.
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Baseline

12 Months

Weight (kg)

65.7±2.1***

101.2±2.5

94.9±2.7###

BMI (kg/m2)

22.2±0.4***

33.9±0.7

31.5±0.7###

Systolic

114.1±1.7

118.6±1.7

117.3±1.7

Diastolic

68.7±1.2

69.0±1.1

68.5±1.2

Fat Mass (kg)

15.1±1.07***

41.7±1.5

36.6±1.6###

TSH (ng/dL)

1.8±0.16

2.2± 0.2

1.9±0.2

Free T4 (ng/dL)

1.24±0.50**

1.12±0.02

1.09±0.03

Total T3 (ng/dL)

100.6±3.1**

112.7±3.1

101.8±2.6###

Reverse T3 (ng/mL)

0.33±0.03*

0.26±0.01

0.26±0.01

Leptin (ng/dL)

9.3±2.2***

39.1±3.6

34.5±3.4

REE (kcal/24h)

1307.5±46.9***

1634.5±47.8

1612.9±43.1

Body Composition Adjusted REE

-

-

1575.9±60.3

Blood pressure (mm Hg)

1

Obesity is a source of considerable
morbidity and early mortality in the
United States and is the result of a
sustained imbalance between energy
intake and energy expenditure (EE)1.
Thyroid hormone (TH) and particularly tri-iodothyronine (T3) play
a critical role in the modulation of
Resting Energy Expenditure (REE)
and substrate metabolism 2 . While
dietary restriction has been shown to
inhibit the Hypothalamus-PituitaryThyroid axis by a fall in leptin,
whether nutrient deficits impact on
peripheral TH metabolism is less
known. A better understanding of
the interaction between moderate
calorie restriction, weight loss, and
TH homeostasis could produce valuable information on the adaptive (or
maladaptive) response to dietary
intervention.
The action of TH in the target
tissues is the result of a multi-level

Intervention Group

Comparison Control and Intervention Group at Baseline: *p<0.05, **p<0.01, ***p<0.001
Comparison Between Baseline and 12 Months: #p≤0.05, ##p<0.01, ###p<0.001
Data Expressed as Mean±SEM

$

control system. This allows the precise time- and tissue-specific delivery
of the hormonal signal via the interaction of T3, the active form of TH,
with its nuclear receptor isoforms3.
The pool of T3 is the net result of
its secretion from the thyroid gland,
the peripheral conversion of the prohormone T4 into T3, and its degradation. Peripheral conversion of T4 into
T3, achieved by the combined actions
of the deiodinases type-1 and type-2
(D1 and D2) is responsible in humans
for a substantial component of the
circulating and tissue pool of TH4.
Forty-seven subjects BMI≥25≤45
Kg /m 2 a nd 30 non- over weig ht

controls were enrolled into the study.
Over weight subjects under went
a one-year individualized calorierestricted diet (~600 Kcal/day deficit)
and were encouraged to increase
physical activity, achieving 5-10%
weight loss. Various metabolic measurements were performed at 0, 1.5,
3, 6, 9, and 12 months.
The inter vention resulted in
6.3±0.9 kg (6.5±1.0%) weight loss
(Table 1). At baseline, TSH and
T3 levels correlated significantly
with fat mass. After weight loss,
T3 decreased significantly (from
112.7±3.1 to 101.8±2.6 ng/dL p<0.001)
in the absence of significant changes
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in T SH or free T4 (f T4). The
decrease in serum T3 correlated
with the decrease in weight. T3: fT4
ratio (used as an index of peripheral
conversion of TH) decreased significantly in individuals who lost >5%
body weight. After correcting T3 for
changes in fat mass, the decrease
from baseline remained statistically
significant. Longitudinally, while
TSH levels had a non-significant
reduction, and fT4 levels showed
a small but significant reduction
(Figure 1 D, E), the decrease in T3
was more robust (p=0.001) (Figure
1C). The decrease in serum T3 correlated with the decrease in weight
(R=0.294, p<0.001). No statistically
significant changes in reverse T3
levels were observed over the course
of the study (Figure 1F).
A relative inhibition of peripheral
5’-deiodination of the pro-hormone
T4 into T3 is likely responsible for
some of the observed changes in the
thyroid homeostasis, as indicated by
the significant decrease in the T3:fT4
ratio, a sensitive index of conversion
of TH in the individuals who had a
greater degree of weight loss5. Our
results indicate that T3 levels closely
correlate with individual nutritional
status, and moderate weight loss
results in a significant decrease in
T3 with minimal changes in other
thyroid hormone homeostasis parameters. The data suggest a decrease
in peripheral conversion of the prohormone T4 into its hormonally
active metabolite T3 is at least in part
responsible for the changes in thyroid
hormone level.

CLINICAL

FIGURE 1: Longitudinal changes in anthropometric and thyroid hormone
homeostasis parameters during the 12-month weight loss intervention.
During the weight loss intervention (Panels A and B) a significant decrease
in serum T3 was observed (Panel C). A trend toward a reduction in TSH
and fT4 was also observed (Panels D and E). No significant difference was
observed in the rT3 serum levels throughout the study. Repeated measure
ANOVA, data are reported as mean±SEM.
REFERENCES
1. Flegal KM, Carroll MD, Ogden CL, Curtin
LR. Prevalence and trends in obesit y
among U.S. adults, 1999-2008. JAMA.
2010;303:235–241.

4. Gereben B, Zavacki AM, Ribich S, et al.
Cellular and molecular basis of deiodinasereg ulated thyroid hormone signaling.
Endocr Rev 2008;29:898–938.

2. Danforth E, Burger, A. The role of thyroid hormones in the control of energy
expenditure. Clin Endocrinol Metab.
1984;13:581–595.

5. Peeters RP, van der Deure WM, Visser,
TJ. Genetic variation in thyroid hormone
pathway genes; polymorphisms in the TSH
receptor and the iodothyronine deiodinases. Eur J Endocrinol. 2006;155:655–662.

3. Braverman L, Utiger R. Werner & Ingbar’s
The Thyroid: A Fundamental and Clinical
Text. New York: Lippincott Williams &
Wilkins; 2004.
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Retinal Ganglion Cell Layer Thickness in Children
with Vision Loss from Optic Pathway Gliomas
Sherry Gu, MSIII
ADVISORS:
Natalie C. Glaug,
B.A.4, Roger J.
Packer, M.D.1,2,3, and
Robert A. Avery, D.O.,
M.S.C.E.1,2,3
The George Washington University School
of Medicine and Health Sciences (SMHS)
1
Department of Neurology, and 2SMHS
Department of Pediatrics, and 3Gilbert Family
Neurofibromatosis Institute, Children’s
National Health System, Washington, D.C.

Low-grade gliomas are the most
common brain tumor in children, and
when they occur in the anterior visual
pathway are called optic pathway
gliomas (OPGs). Accurate and reliable vision testing in young children
with OPGs can be limited by their
cooperation. However, since not all
OPGs cause vision loss, a surrogate
marker of visual pathway integrity
that does not require cooperation
would be helpful.
Spectral-domain optical coherence tomography (SD-OCT), the

optical analog of ultrasound imaging,
has emerged as a relatively noninvasive and time-efficient way to image
the retina. When the visual pathway
is damaged distally, the thickness
of the unmyelinated retina will
decreased due to axonal degeneration. SD-OCT has proven to allow
for safe, quantitative measuring
of important retinal layers such as
the ganglion cell layer-inner plexiform layer (GCL-IPL). We explored
whether structural measures of the
macular GCL-IPL using SD-OCT
were related to visual acuity (VA)
and visual field (VF) in children with
OPG.
Children with OPGs (sporadic or
secondary to Neurofibromatosis type
1, NF1) enrolled in a prospective study
of SD-OCT were analyzed. Enrolled
subjects were included only if macular
SD-OCT images were acquired and
they were cooperative for VA and VF
testing. Manual segmentation of the
macular GCL-IPL was performed
across an Early Treatment Diabetic
Retinopathy (ETDRS) grid at 1.5,
3.0 and 4.5mm diameter. GCL-IPL

thickness measures (microns) were
compared to VA and VF outcomes.
Forty-seven study eyes from 26
children with OPGs (18 NF1-related,
8 sporadic) were included, with a
median subject-age of 5.3 years (range,
2.5 – 12.8). The GCL-IPL thickness
(3.0mm diameter) was decreased in
the abnormal VA (61 ± 2 microns),
abnormal VF (73 ± 11 microns) and
abnormal VA/VF (53 ± 5 microns)
groups when compared to the normal
VA/VF group (92 ± 9 microns; F =
44.9, p < 0.001). GCL-IPL thickness in the abnormal VA group was
not different from the abnormal
VF (Post-hoc Scheffe’s test, p = .28)
and abnormal VA/VF groups (p =
0.67), however the abnormal VA/VF
group had a lower GCL-IPL than the
abnormal VF group (p < 0.01).
Children with vision loss (VA,
VF, or both) from their OPG have
decreased ganglion cell later-inner
plexiform layer (GCL-IPL) thickness compared to those children with
normal vision. GCL-IPL thickness
could be used as a surrogate marker
of vision in children with OPGs.

Safety and Efficacy in Nonendoscopic
Transaxillary Breast Augmentation:
A Safe and Cost-Effective Procedure that Maximizes
Satisfaction and Minimizes Complications
Robert John
Hagenberg,
CPA, MSIII
ADVISOR:
George J. Bitar,
M.D., FACS
Bitar Cosmetic Surgery Institute
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The submuscular transaxillary breast
augmentation (TBA) is an established
and preferred procedure for breast
augmentation due to the limited visibility of scar tissue, efficient sculpting
of the implant pocket, and low rate of
complication1. The objective of this
study is to compare the complication rates of a nonendoscopic TBA

approach to an endoscopic approach
and to assess patient satisfaction
with nonendoscopic TBA. A series
of 353 TBAs were performed with
saline implants and followed up by
the senior author over a course of
eight years, each at the same Level 1
trauma hospital with the same group
of anesthesiologists under either
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general or laryngeal mask anesthesia
(LMA). A retrospective chart review
was conducted to ascertain complication rates and a literature review
was performed to compare the rate
of complication of endoscopic to
nonendoscopic TBAs. Additionally,
satisfaction surveys were sent to the
353 nonendoscopic TBA patients
via mail, email, and phone. The
total complication rate, including a
range of minor complications such
as superficial infection to major

complications such as hematoma
requiring implant removal, was 9.92%
(95% CI- 7.22-13.48%). See Table 1
for a detailed breakdown and comparison between this nonendoscopic
approach and literate detailing risk
profiles of an endoscopic approach
to TBAs. The complication rates of
this non-endoscopic procedure are
similar to the complication rates of a
review of endoscopically guided TBA
literature. Of the 353 patients, satisfaction rates were received from 186

or 52.69%. Of those who responded,
the breakdown of satisfaction survey
received by medium includes 32.8%
by email, 19.4% by standard mail, and
47.8% by phone. Level of satisfaction
was measured on a 1–5 scale, 1 being
poor and 5 being excellent, patients
rated their nonendoscopic breast
augmentations a mean of 4.46 (st.
dev. 0.85) with a mean follow up time

SAFETY AND EFFICACY
Continued on p. 10

TABLE 1: This study’s breakdown of complication rates and side-by-side comarison with other TBA studies.
(Bitar, et al, 2012)
— This Study

(Momeni,
2006)

(Howard,
1999)

(Kolker,
2010)

(Nohira,
2004)

(Tebbetts, (Tebbetts,
2006)
2006)

(Huang,
2012)

(Garcia,
2010)

(64 Subfascial,
(22 Sub13 Subfascial,
muscular, 309 Sub282 Dual muscular)
Plane)

Submuscular
TBA

Submuscular
TBA

Placement

Submuscular TBA

Submuscular
TBA

Submuscular
TBA

Submuscular
TBA

Submuscular
TBA

Endoscopic Assistance?

No

Yes

Yes

Yes

Yes

Yes

No

No

No

Total Number of Implants

353

47

58

197

160

359

331

1,682

344

4.23%

1.90%

Major Complications
Capsular Contracture (Baker III/IV)

Number of
Complications

%of Total
Patients

8

2.27%

% of Total Implants
2.13%

1.72%

0%

6.88%

1.39%

1.72%

0%

2.50%

0.28%

Ripling

2

0.57%

Hematoma

1

0.28%

Mastitis

0

0.00%

Sponaneous Implant Rupture

4

1.13%

Implant Extrusion

2

0.57%

High-Riding Implants (No Resurgery)

2

0.57%

0%

High-Riding Implants (with Resurgery)

2

0.57%

2.54%

Total High-Riding Implants

4

1.13%

Breast Asymmetry

2

Low-Riding Implants

1

Total Malaligned Implants

0.54%
0%
1.72%

2.03%

6.38%

0.06%

2,72%

3,57%

0.28%

1.81%

0.57%

1.52%

1.11%

3,32%

0.28%

1.02%

1.98%

6

1.70%

2.03%

Cellulitis

0

0.00%

0.00%

0

0.00%

1

6.38%

1.72%

4

1.13%

2.13%
(“Ptosis”)

Total

35

9.92%

10.81%

1.70%
1,70%
0.58%

5.08%

1.39%

5.14%

0%

0%

0%

0%

0%

1.02% (1
Intraop.
Hemorrhage,
1 Unilateral
Arm Hypoesthesia)

0.56%

1.81%

4.74%

13.90%

0.28%

Other

CLINICAL

0%

2.54%

7

Seroma

0.12%

0.85%

Hypertrophic Scar
Decreased Nipple Sensation

1.11%

0%

2.97%

3.98%

0.06%

6.17%

9.22%

11.00%

1.02%

6.90%

11.17%

9.38%
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of 131.43 weeks (st. dev. 75.72) with a
range from 1 to 470 weeks. Due to
a high patient satisfaction rate and
comparable complication rates, the
non-endoscopic approach to transaxillary breast augmentation is a safe,
elegant, cost effective, and reputable
procedure maximizing satisfaction
and minimizing complications.
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Although musculoskeletal complaints have long been associated
with spine pain, a limited number
of investigations have sought to
correlate tender points and trigger
points with spinal patholog y. A
tender point, typically a hallmark of
myofascial pain syndrome, is a point
within a muscle that is painful upon
local palpation. A trigger point, typically a hallmark of fibromyalgia, is a
point within a muscle that produces
radiating pain upon palpation 2 .
Cyriax suggests that tender points
may be referred from cervico-thoracic, lumbro-sacral, and/or neural
structures1. The current study was
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designed to determine whether
pain perceived at the tender points
or trigger points of several specific
muscles of either the upper limb or
the lower limb correlates to the site
of injury, lesion, or pathology in the
spine. A better understanding of
pain referring to tender and trigger
points from spinal and/or neural
structures may allow for more effective therapies directed at the source
of the pain, the spinal pathology,
as opposed to the tender or trigger
points themselves.
Following IRB approva l, we
performed a prospective, observational study of 50 subjects presenting
with cervico-thoracic or lumbrosacral spine pain that may or may
not radiate to the upper and lower
extremities respectively. Excluded
patients included those with a BMI
greater than 30, a history of prior
neck or back surgery, receiving or
applying for disability compensation,
undergoing litigation related to the
injury, or the history of an epidural
steroid injection within the last

three months. Algometry was used
to measure the minimum pressure at
which the patient begins to feel discomfort, as opposed to maximal pain
threshold. The algometer measures
the pain pressure threshold at each
muscle site in kg/cm2, with a stopping point of 4 kg/cm2 (roughly the
pressure required to cause an examiner’s nail to blanch while testing
these points manually), as is done per
the standard of care.3 If the patient
feels local pain only upon algometer
application, he is said to have a tender
point in that given muscle. If the
patient feels radiating pain, he is said
to have a trigger point. If the patient
does not experience pain before the
algometer reads 4 kg/cm2 of force,
it is deduced that the patient has
neither a tender nor a trigger point in
that muscle. Algometery was used to
obtain pain-pressure threshold measurements of 10 muscles of the upper
extremity and neck and 6 muscles of
the lower extremity.
Of patients with cervico-thoracic
pain, 61% were found to have tender
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points and/or trigger points in specific muscles. Patients with lesions
in C3-C4 presented more commonly
with both tender points and trigger
points located in the deltoid, trapezius, pectoralis major and triceps
brachii; C5-C6 lesions with tender
points in the latissimus dorsi, pectorlais major, and triceps brachii;
C5-C6 lesions with trigger points in
the deltoid, biceps brachii, and pectoralis major; and C6-C7 lesions with
tender points in the pectoralis major,
latissimus dorsi triceps brachii, and
biceps brachii. Of patients with
lumbro-sacral pain, 58% were found
to have tender points and/or trigger
points in specific muscles. Patients

with lesions in L4-L5 presented more
commonly with tender points located
in the vastus medialis, adductor
longus, and gluteus maximus; L4-L5
lesions with trigger points in the
gluteus maximus; L5-S1 lesions with
tender points in the vastus medialis,
tibialis anterior, and gluteus maximus; and L5-S1 lesions with trigger
points in the gluteus maximus. The
majority of diagnoses included spondylosis, degenerative disc disease,
disc bulging, and spinal stenosis.
These preliminary results suggest that tender and trigger points of
selected upper and lower extremity
muscles are correlated to spinal
pathology. Therefore, therapy should

be targeted at the corresponding
spinal lesion. We expect to enroll a
minimum of 100 subjects in this trial.
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Resistive Index (RI) calculated by
Spectral Doppler ultrasound of the
testis is a safe, non-invasive indicator
of the intratesticular microcirculation. The current body of literature
has shown that RI is related to spermatogenesis, with an elevated RI
indicating dyspermia. However, the
literature does not specify locations
in the testis where the RI is best
measured. It is the goal of this study
to evaluate measurement of RI from
multiple areas in the testes to determine if significant differences exist.
A retrospective review of all testicular ultrasounds performed at our
clinic from September 2011 through
August 2012 yielded 214 patients
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and 418 testicles (10 patients with
solitary testis). Spectral Doppler
interrogation of a single centripetal
or recurrent rami artery from the
upper, middle and lower portions of
each testis was performed using a BK
medical Flex focus ultrasound with
an 18 mHz linear array transducer by
a single sonographer.
The average RI for the right and
left was 0.56. When comparing the
right and left testis there was no statistical difference (p-value of 0.86).
In the right testis, there was no statistical difference when comparing
the upper and lower values (average
RI 0.56 and 0.56, respectively) to
the mid-testis (average RI 0.56) with
p-value of 0.68 and 0.79, respectively.
There was also no statistical difference when comparing the right upper
to the right lower testis, with p-value
of 0.48. In the left testis, there was
no statistical difference when comparing the upper and lower values
(average RI 0.56 and 0.57, respectively) to the mid-testis (average RI
0.56) with p-value of 0.95 and 0.70,

respectively. There was also no statistical difference when comparing
the left upper to the left lower testis
with p-value of 0.73.
Spectral Doppler ultrasound is
a safe, non-invasive technique that
adds unique real-time information
about the intratesticular microvasculature and testicular function. This
study found that the RI measurements are not statistically different
when measured from the upper, mid,
or lower testis. Therefore, as the use
of RI as an assessment of testicular
function increases, this work suggests that measurement of the RI can
be taken from any area in the testis
with equivalent results. The process
of identifying an intratesticular
artery and calculating the RI in the
upper, middle, and lower pole of each
testis can be time consuming. The
ability to use a single measurement
of RI from anywhere in the testis
might encourage urologists to obtain
this measurement as an independent
marker of testicular function.
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Children with congenital heart disease often require surgical procedures
at a young age. Thromboembolic
complications (TC) are a major
source of post-operative morbidity
and mortality in children undergoing
cardiac surgery with cardiopulmonary bypass (CPB). Thrombosis proceeding pediatric cardiac surgery are
associated with platelet dysfunction,
blood hypercoagulability, inflammation, and disruption of blood flow. In
addition, patients’ immature coagulation system results in characteristically low capacity to inhibit clot
formation and elevated resistance to
anticoagulants.1, 2, 3
Data on th rombosis associated with pediatric cardiac surgery
are limited and hence association

10

between TCs and surgical outcomes
in this population is not well understood. In a retrospective study, 1,542
pediatric cardiac surgeries performed
from September 2004 to December
2007 were quantified and characterized for post-operative TCs and
surgical risk factors respectively.
Ten percent of the patients (152/1,542)
were identified to have TCs. Of those
patients, in-hospital mortality for all
causes was 15% (23/152), while TCs
served as a primary or a secondary
cause in 12/23 (52%) of all deaths. In
addition, isolated intracardiac TCs
or TCs in multiple vascular systems
were associated with more than
double the risk for cardiac arrest
(P=0.04) and mortality (p=0.009)
relative to patients with isolated
intra-venous or intra-arterial TCs.
These findings suggest that TCs after
cardiac surgery are significantly associated with poor clinical outcomes
and occur at a higher rate compared
to the overall cases of thrombosis in
the pediatric population.
To further investigate this matter,
a large-scale cross-sectional study
is currently in progress. This study
includes experimental laboratory

investigations, diagnostic protocols,
and long-term patient follow-up. This
would serve to strengthen previous
findings and help further enhance
the current understanding of TCs
with respect to quantification, characterization, and risk stratification.
The goal is to permit the development of effective tools necessary for
prevention and early identification
of TCs instead of treatment alone.
Accordingly, clinicians can identify
patients that may require more
aggressive thromboprophylaxis,
enhance assessment post-operatively,
and implement more aggressive treatment strategies.
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Exercise plays a major role in the
prevention and management of Type
2 Diabetes (T2D) by increasing the
rate at which skeletal muscle cells
take up glucose. A number of clinical
trials have illustrated that moderate
physical activity and proper diet can
decrease the progression of impaired
glucose tolerance as seen in T2D1,3.
Individuals with T2D participating
in exercise interventions greater
than eight weeks duration had significantly lower HbA1c levels than
the individuals who did not exercise
— highlighting the importance of
regular exercise for T2D patients2 .
Recent genetic studies examining
T2D have implicated genes involved
in several potential therapeutic pathways involving those associated with
β-cell dysfunction, insulin packaging
and secretion. One variant, highly
associated with T2D, was a nonsynonymous change in the SLC30A8
gene that encodes for the Zinc
Efflux Transporter 8 protein (ZnT-8)
expressed mainly in the β-cells of the
pancreas — responsible for storing
and releasing insulin. The variant
in SLC30A8 (rs13266634) gives rise
to a Tryptophan at amino acid 325
in place of an Arginine, resulting
in a defective ZnT-8 protein. In the
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FIGURE 1

FIGURE 2
absence of a properly functioning
ZnT in vesicles, insulin cannot be
synthesized and stored appropriately, disrupting glucose uptake
and Adenosine triphosphate (ATP)
formation downstream. The primary objective of our study was to
determine whether there is a link
between exercise capacity and the
SLC30A8 (rs13266634) variant gene.

We hypothesized that this variant in
the SLC30A8 gene may help explain
differences in muscle response to
exercise, possibly due to insufficiency
in glucose uptake and ATP synthesis.
Two cohorts with a total of 697
participants were subjected to one
of two interventions to determine

SLC30A8 GENE Continued on p. 14
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FIGURE 3

FIGURE 4

the effects of exercise on muscle.
Our results indicated that rs13266634
variant is strongly associated with
several different muscle phenotypes
in men but not in women. Male
carriers of the common allele were
more likely to demonstrate greater
post-workout strength loss and
greater perceived soreness (Figure 1).
Increased markers of muscle damage
— creatine kinase (Figure 2) and myoglobin (Figure 3) — were also strongly
associated with the common allele.
Furthermore, affected heterozygotes
(CT) and homozygotes (CC) were
more likely to have decreased baseline whole muscle volume (Figure 4)
and decreased baseline 1-repetition
maximum strength (Figure 5).
In this era of increasing interest
in personalized medicine, there is
an intense search for genetic markers
that can be used in preventing and
managing T2D. Clinically, the outcome of our study may help identify patients for whom resistancetraining is an optimal first-line
therapy in the management and
treatment of T2D. We have demonstrated that the rs13266634 variant in
SLC30A8 may be used as an indicator
for those individuals who may not
respond to exercise as the first-line
therapy for T2D, and may require
an alternative method to manage
their impaired glucose tolerance.
Additional research is needed to
determine if the presence of this
single-nucleotide polymorphisms
(SNP) and predisposition to postexercise soreness leads to a decreased
desire to be active, thus, promoting
a more sedentary lifestyle, further
amplifying their risk of developing
T2D. We are intrigued by the notion
that this SNP might influence several
facets of T2D progression.

FIGURE 5
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For youth with Type 1 Diabetes
(T1D), adolescence is characterized
by a period of poor adherence. One
reason for poor adherence may be
related to youth establishing their

independence, including making
their own nutritional choices1. Quality
nutrition is strongly recommended
to improve health (e.g. lower LDL
plasma levels), and potentially offset
risk factors for cardiovascular (CV)
disease in individuals with T1D2. Our
objective was to evaluate the rates of
adherence to nutritional guidelines in
youths with T1D and to examine the
association of nutritional quality and
Hemoglobin A1c (HbA1c).
Baseline data from a randomized
controlled trial of an intervention
designed to prevent deterioration of
glycemic control in young adolescents
with T1D were evaluated. Adolescentparent dyads (n = 257, youth mean age =
12 years, SD = 1.2 years, 49.4% female,

64% intensive insulin regimen, mean
HbA1c = 8.8, SD = 1.6) reported dietary
intake via two 24-hour recall interviews as a component of their diabetes
self-care. Participants were stratified
by insulin regimen. Participants who
reported four or more injections or
use of an insulin pump were considered intensive. Conventional therapy
involved a more structured insulin
regimen including a set amount of
carbohydrates and insulin intake per
meal and fewer injections. Intensive
therapy offered greater flexibility
with calculating insulin needs, based
on insulin to carbohydrate ratios,
for each food consumed. Dietary
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FIGURE 1: Participants Who Met Dietary Recommendations
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intake was scored using The Food
Processor® Nutrition Analysis
Software (ESHA Research, Salem,
OR, USA). Demographic variables
and HbA1c data were abstracted from
questionnaires and medical charts.
When compared to the American
Diabetes Association (ADA) and
International Society for Pediatric
Diabetes (ISPAD) recommendations,
many youths were not meeting nutritional guidelines. This included percent daily intake of protein, carbohydrates, fat, saturated fat, cholesterol,
and dietary fiber. Furthermore, 50.2%
of participants reported LDL cholesterol levels greater than recommended
guidelines for primary prevention
of CV disease in youths with T1D3.
Significant positive correlations were
found between HbA1c and percent of
total calories from fat (r = .24, p < 0.01),
polyunsaturated fat (r = .16, p < 0.05),
dietary cholesterol (r = .20, p < 0.01),
and LDL (r = .24, p < .01). Significant
negative correlations were identified
between HbA1c and percent of total
calories from carbohydrates (r = -.23,
p < 0.01) and dietary fiber (r = -.13, p
< 0.05).
The majority of early adolescents
with T1D did not meet nutrition
guidelines. This may place them at
increased risk for CV diabetes-related
complications, which was suggested by
increased LDL plasma levels reported
in this adolescent study population.
Further, several indices of nutrition
were associated with glycemic control,
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TABLE 1: Recommended Guidelines for Adolescents with Type 1 Diabetes
Recommendation

Reference

% calories from carbs

50–55%

ISPAD

% calories from protein

15–20%

ADA

% calories from fat

30–35%

ISPAD

% saturated fat

< 7% of total calories

ADA

Polyunsaturated fat

< 10%

ISPAD

Monounsaturated fat

10–20%

ISPAD

Cholesterol

< 200mg/day

ADA

Dietary Fiber

14g/1000kcal

ADA,
HP2010

BMI

Overweight 85th–94th percentile (25.0–29.9 kg/m2)
Obese ≥ 95th percentile (≥ 30kg/m2)

ADA

Blood Pressure

130/80 mmHg or 90th percentile for
age, sex, and height

ADA

LDL cholesterol

< 100mg/dL

ADA

ISPAD = International Society for Adolescent and Pediatric Diabetes; ADA = American Diabetes
Association; HP2010 = Healthy People: 2010

suggesting that there may also be a
short-term impact linked to failure
to adhere to nutritional guidelines.
In addition to monitoring blood
glucose levels, HbA1c has utility as a
risk factor for CV disease. Our study
supports a link between nutritional
intake, HbA1c, and risk factors for
CV disease. Diabetes education
efforts regarding healthy eating and
dietary management may need to be
enhanced to achieve recommendations and ultimately improve health
outcomes for those with T1D.
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Venous thromboembolism (VTE)
is a serious, potentially deadly, postoperative morbidity that occurs in
up to 34.6% of gynecologic oncology
patients who do not receive anticoagulant prophylaxis1. VTE refers to
both deep vein thrombosis (DVT) and
pulmonary embolism (PE). A DVT is
a blood clot in a deep vein, typically
originating in the leg, which runs the
risk of dislodging and traveling in the
bloodstream up to the lungs at which
point it can become a life threatening
PE. Roughly 200,000 deaths each
year are caused by PEs and non-fatal
instances of VTE result in prolonged
hospitalization and outpatient care.
While the American College of
Chest Physicians (ACCP) recommends anticoagulant prophylaxis in
the general surgical oncology population, no specific recommendations
are available in regards to how long to
extend prophylaxis for patients within
this patient population2. AACP guidelines for these patients are based upon
studies with small sample sizes and
they tend to group all gynecologic
oncology patients into one cohort.
We hypothesized that the timing
of perioperative prophylaxis, patient
age and BMI, tumor type and histology, and mode of surgery (laparoscopy versus laparotomy) are important risk factors in this gynecologic
oncology patient population. To
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investigate this, we performed a retrospective cohort study of 527 gynecologic oncology patients who underwent surgery from 2008 through 2011
at a major academic institution. Prior
to Jan. 1, 2010, gynecologic oncology
patients were given post-operative
subcutaneous heparin three times
daily, total ionizing dose (TID), and
they wore sequential compression
stockings. Starting Jan. 1, 2010, in
addition to the postoperat i ve hepa r i n
TID and sequential
compression stockings, oncology patients
u nderg oi n g m ajor
gynecologic surgery
were given a preoperative dose of heparin
and two weeks of postoperative low molecular weight heparin
after discharge.
Of our cohort of 527 patients, 28
occurrences of VTE were noted (11
DVT and 17 PE). In comparison to
patients with no incidence of VTE,
patients with VTE were older (mean
age 64 vs. 54, p < 0.001) and had a
higher BMI (32 vs. 29, p=0.048).
We found that malignancy, blood
transfusion, surgical tumor debulking, and wound infection were all
significantly associated with VTE
(p<0.001). Features of malignancy, in
particular tumor grade and histology,
were found to be statistically significant. We noted a VTE incidence of
15.1% in patients with grade three
tumors in comparison to only 1.7%
incidence in those with grade one or
grade two tumors (RR 8.66, p<0.001).
We hypothesized that three tumor
histologies — clear cell, serous, and
malignant mixed Mullerian tumor
(MMMT) — put patients at a greater

risk for developing a VTE. In a multivariate analysis, these three tumor
histologies were 7.4 times more likely
to be associated with a VTE event
compared to all other histologies in
our study (p<0.001).
As previously mentioned, the
ACCP guidelines offer prophylaxis
guidelines that apply to the entire
gynecologic oncology patient population. We found that patient age, BMI,

Roughly 200,000 deaths each year
are caused by PEs and non-fatal
instances of VTE result in prolonged
hospitalization and outpatient care.
tumor grade and histology, as well as
the nature of surgical intervention,
were relevant risk factors for the
occurrence of VTE. Our study suggests that further research on risk factors for VTE within the gynecologic
patient population is warranted, as
it may inform future clinical guidelines that would enable physicians to
tailor the extension of anticoagulant
prophylaxis based upon individual
patient need. Current validation of
a clinical prediction rule for gynecologic oncology surgery is underway.
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Care provided in the Emergency
Department (ED) is often the first
and only treatment for many people,
and prior research has shown that
the ED is used frequently by persons
with mental health conditions1, 2. In
2007, 12.5% of the 95 million ED
visits were attributed to mental
health and/or substance abuse 3 .
ED physicians increasingly come
into contact with patients suffering
from issues such as major depressive

levels working with this population by assessing the ED residents’
attitudes toward diagnosing and
treating patients who come to the
ED with depression as compared to
two other common disorders that the
residents encounter — diabetes and
hypertension.
Participants were asked how
comfortable they were making a new
diagnosis of hypertension, diabetes
mellitus (DM), and MDD using
a 5 point Likert scale in which “1”
represented strongly disagree and
“5” represented strongly agree. We
also examined comfort levels with
prescribing medications for MDD
compared to hypertension and diabetes in three scenarios. The first
without follow-up (no primary care
provider (PCP); the second with
a PCP available for follow-up but
without speaking to him/her; and
the third with an available PCP that
is reachable by phone. We also exam-

Residents exhibited significantly lower levels of comfort

(95% CI 3.52, 4.48). Residents were
less comfortable prescribing medication for depression as compared to
hypertension or diabetes across all
scenarios. The most common barrier
to treatment was lack of comfort with
treating patients without follow-up.
Residents have a low level of comfort in treating MDD as compared
to conditions such as hypertension
and diabetes. Further research is
needed to examine residents’ attitudes toward diagnosing and treating
depression, and its perceived barriers.
Limitations of the study include the
small sample size. Our study suggests that ED residents may benefit
from additional training in diagnosis
and treating MDD. Due to the high
number of MDD patients who use
ED services, resident curriculums
may benefit by promoting a stronger
emphasis on MDD diagnosis and
treatment.
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Biomedical:
Identifying Directional Secretomes of In Vitro
Differentiated Normal Primary Bronchial Epithelium
Eric Johnson,
MSIII
ADVISOR: Dinesh
Pillai, M.D.
Research Center for
Genetic Medicine,
Children’s National Health System

Airway epithelium is recognized as
a key tissue in studying lung diseases
based on its role as a polarized, differentiated barrier.1 It simultaneously
responds to airborne pathogens and
environmental challenges at the
apical surface while creating local
and systemic changes based on these
external stimuli.2 Proteins secreted
apically and basally by epithelial
cells are likely to be part of a critical
signaling network between airway
environment and systemic milieu.
Alterations in the airway epithelial
barrier may lead to dysregulated signaling and subsequent clinical symptoms observed in many lung diseases
such as: asthma, bronchitis, and cystic
fibrosis. In asthma, previous studies
have demonstrated that allergen
challenge tests result in upregulation
of many proteins associated with
inflammation, eosinophilia, airway
remodeling, tissue damage, and
mucus production relative to nonasthmatics.3 These studies on ex vivo
airway samples suggest that through
the application of proteomic techniques, such as Western Blot, ELISA,
and flow cytometry to in vitro models,
may provide a unique opportunity
for global understanding of protein
interactions for a given disease state
and mechanisms.4

CLINICAL

TABLE: Differentially Expressed Proteins in Apical vs Basolateral Compartments
Uniprot ID

Protein*

Location†

P Value‡

Fold Change§

Q16787

Laminin subunit alpha-3

Secreted

0.032

-12.71

O75635

Serpin B7

Cytoplasm

0.048

-3.17

P32119

Peroxiredoxin-2

Cytoplasm

0.037

1.70

P30086

Phosphatidylethanolamine-binding Cytoplasm
protein 1

0.023

1.81

P35241

Radixin

Exosome

0.035

2.77

P60709

Actin, cytoplasmic 1

Cytoplasm

0.002

2.91

P63261

Actin, cytoplasmic 2

Cytoplasm

0.002

2.91

P68133

Actin, alpha skeletal muscle

Cytoplasm

0.042

3.08

P15311

Ezrin

Exosome

0.003

4.87

P28070

Proteasome subunit beta type-4

Cytoplasm

0.037

5.23

P27348

14-3-3 protein theta

Cytoplasm

0.019

5.99

P20618

Proteasome subunit beta type-1

Cytoplasm

0.036

6.25

Q04917

14-3-3 protein eta

Unknown

0.039

6.73

P02768

Serum albumin

Secreted

0.036

11.20

(Apical/Basal)

* Identified in all apical and basolateral secretions with differential expression based on Student T-test.
† Location based on Uniprot and SignalP databases; exosome distinction based on previous study(16)
‡ Based on two tailed Paired Student T-test; only proteins with p<0.05 are listed.
§ Based on average normalized spectral count calculated in ProteoIQ. Positive value denotes increased
expression in apical secretions; negative value denotes increased expression in basolateral
secretions.

Our recent data demonstrated
that bronchial epithelium in treated
asthmatics have only basolateral
increases of specific cytokines compared to non-asthmatics, which
have both apical and basolateral
seceretions.5 To our knowledge, no
study has characterized the apical
and basolateral secretomes of airway
epithelium. Defining these secretomes in normal in vitro Human
Bronchial Epithelial (HBE) models
would lay the foundation for future
comparative studies in disease. Our

bioinformatic analysis of significant
proteins identified in both apical and
basolateral secretions detected several biological processes that appear
homeostatic in nature with subtle,
yet significant, differences in the
distribution of these process between
apical and basolateral secreted proteins (see Table). Our results revealed
that certain proteins were secreted
only into the apical or basolateral

DIRECTIONAL SECRETOMES
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compartments of the tissues and
others were differentially secreted
between these two compartments.
All samples tested demonstrated
through proteomic evaluation, that
the epithelial layer directionally
expresses proteins and that the purpose of this is functional in nature.
In this study we successfully characterized directional in vitro normal
airway secretomes through comprehensive evaluation of apical and basolateral secreted proteins. Specifically,
we identified the normal apical and
basolateral secretomes in the gold
standard model for studying mechanisms of airway diseases — in vitro

primary differentiated bronchial
epithelium. We identified intrinsic
proteins uniquely expressed in both
compartments and differentially
expressed between compartments
in cell cultures from multiple donors.
Future validation of this in vitro
secretome model in ex vivo specimens
will enhance our understanding of
lung diseases. In addition, by establishing a model to test ex vivo tissue
in in vitro technique, we have highlighted potential therapeutic markers
that can be used in future airway
secretome studies to allow for a more
efficient and practical path towards
personalization of medical care.
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An Alternative Replication Pathway Induced by Apoptosis
in Cell Lines Latently Infected with Human Herpesvirus
Jill Remick, MSIII
ADVISORS: Steven
Zeichner, M.D., and
Alka Prasad, Ph.D.
Children’s National
Health System

Human herpesviruses (HHV) are
characterized by their unique ability
to productively infect or remain
latent in the host cell. The initiation of lytic replication can be
induced by external or internal
stimuli, such as cytokines or chemokines. Chemical agents such as
tetradecanoylphorbol-13 –acetate
(TPA), which stimulate cell signal
transduction pathways, can also
induce viral replication.1 For Kaposi’s
Sarcoma-associated Herpesvirus
(KSHV or HHV-8), the viral protein that was thought to trigger
the cascade of events leading to
lytic replication was the replication
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and transcription activator protein
(RTA).2 In an initial attempt to characterize genes expressed while RTA
was inactivated, an unexpected event
was observed, in which agents that
induce apoptosis appeared to trigger
KSHV replication suggesting that
an alternative replication program
induced by host cell apoptosis can
initiate KSHV replication in the
absence of RTA.3
The question is whether this
alternative replication program is
unique to KSHV or if it is a common
feature of all herpesviruses. In particular, we focused our efforts on
HHV-4 (also known as Epstein Barr
Virus or EBV), HHV-6B, HHV-6A
and HHV-7. If apoptosis appears to
induce replication we can conclude
this may be a common feature of the
herpesvirus.
Here we show that 2[[3-(2,3-dichlorophenoxy)propyl]amino] ethanol
(DCPE), induces apoptosis in cell
lines latently infected with EBV,

HH V-7, HH V- 6B, a nd - 6A by
staining cells with annexin V and
propidium iodide (PI) and measured
using flow cytometry. Annexin V
targets a protein, phosphatidylserine, expressed on the surface of
cells undergoing early apoptosis.
Propidum iodide binds to DNA and
cannot permeate viable cell membrane so effectively detects cells in
late apoptosis. Results for EBV and
HHV-7 are shown in Figure 1. The
known viral replication-inducing
agent TPA was used as a positive
induction control for normal viral
replication. Cells latently infected
with KSHV were also used as a
positive control, since the alternative apoptosis-induced replication
pathway for this virus has already
been shown to exist.
We showed t h at apoptot ic
inducing agent, DCPE, induces
viral replication in EBV and HHV-7
latently infected cel ls lines by
RT-PCR assays for viral DNA.
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There was a significant increase in
the amount of viral DNA in EBV
and HHV-7 latently infected cell

lines as compared to the untreated
cells when treated with either TPA
or with apoptotic inducing agent,

FIGURE 1: 2,3 DCPE induces apoptosis in cell lines latently infected
with herpesvirus measured by flow cytometry. Latently infected cell
lines were treated with TPA or 2,3 DCPE for 24hrs and then stained with
annexin V and propidium iodide (PI) and measured by flow cytometry.
A high percentage of cells treated with 2,3 DCPE showed annexin V and
PI positivity. Note: lower left quadrant represents % live cells (annexin
V - and PI - ), lower right quadrant represents % cells in early apoptosis
(annexin V + and PI - ), upper left quadrant represents % cells in late
apoptosis (annexin V - and PI +), and upper right quadrant represents
% cells in early and late apoptosis (annexin V + and PI +).

DCPE (Figure 2). We were not able
to quantify viral DNA in HHV-6A
and -6B latently infected cells likely
due to the primers that were used.
Additional experiments to quantify
the viral DNAs are in progress.
Lastly, we demonstrated viral protein expression induced by apoptosis
occurs for KSHV, HHV-4, HHV6B, and HHV-7 latently infected
cell lines by targeting virus-specific
proteins with primary and secondary
antibodies that were then visualized
by confocal microscopy.
Overall, our data suggests that
an alternative apoptosis-triggered
replication program appears to be a
general feature of the herpesvirus.
The presence of an alternative replication pathway shown in EBV and
HHV-7 latently infected cell lines is
not surprising due to their close taxonomical relationship with KSHV,
as well as the evolutionary benefit
an apoptosis-induced alternative
replication pathway would provide.
Cytotoxic therapy is often required
to treat neoplasms caused by these
viruses including Kaposi’s sarcoma
and Burkitt’s lymphoma caused
by KSHV and EBV, respectively.
Therefore, it may prove beneficial
to treat neoplasms caused by these
viruses with antiviral agents in addition to cytotoxic therapy.
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The Search for Novel Atopic Dermatitis Therapies:
β-Defensin-Inducing Plant Extracts
Ryan Vesny, MSIII
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University of Florida
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Medicine

Beta defensins are antimicrobial
peptides that are part of the innate
immune system and produced by the
skin to combat skin infections.1 The
skin of atopic dermatitis patients is
deficient in these peptides, which may
increase their susceptibility to recurrent skin infections. These infections
occur due to the significant barrier
disruption, chronic skin inflammation, and impaired innate immune
response that are characteristic of the
disease.2 Compounds that induce the
production of beta defensins in the
skin without concurrently inducing
inflammatory cytokines have potential use in atopic dermatitis therapy

and screening methods have been
developed to screen plant extracts
with this profile.3
Two such extracts, dubbed Extract
A and Extract B, were identified that
showed promise in this area. Each
was tested on cultured keratinocytes
from normal and atopic beagles to see
if they induced the production of beta
defensin (BD103), which is analogous
to human beta defensin 3 (hBD3),
without increasing inf lammatory
mediators. This was accomplished by
allowing the keratinocytes to reach
confluence and remain in that state
for two days. They were then starved
overnight in starving media and
placed in starving media containing
the concentrations of the extracts for
24 hours, along with positive (IL-1b
100 ng/ml) and negative (Dulbecco’s
Phosphate-Buffered Saline) controls. The production of BD103
was assessed following application
of increasing concentrations of the
extracts (0.2%, 0.4%, 1% for Extract

FIGURE 1: Extract A relative increase in beta-defensin
103 mRNA to baseline
20

A and 0.2%, 0.4%, 1%, 1.5%, 2% for
Extract B) to the keratinocytes using
quantitative real-time PCR, while
two mediators of inflammation, IL-8
and TNF-α, were assessed using
ELISA.
Analysis of the PCR and ELISA
results was done through independent paired t-testing on mean values
to determine statistical significance
(P < 0.05). Extract B at 2% showed
a significant increase in TNF-α
in atopic keratinocytes compared
to baseline (negative control) and
normal keratinocytes, while also
showing a significant decrease in
IL-8 in normal keratinocytes compared to baseline. At 1.5%, Extract
B showed a significant increase in
BD103 in atopic keratinocytes compared to baseline, while also showing
a significant decrease in IL-8 in
atopic keratinocytes compared to
baseline. Extract A at 1% showed
in both atopic and normal keratinocytes a significant increase in IL-8

FIGURE 2: Extract B relative increase in beta-defensin
103 mRNA to baseline
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compared to baseline, as well as at
0.4% in atopic keratinocytes compared to baseline. Extract A appeared
to have the opposite effect to what
is desired because it increased an
inflammatory marker, IL-8, without
increasing BD103 production.
The results from Extract B (1.5%)
show that pursuing further testing
on not only Extract B, but also other
plant-based compounds that, through
screening, show pro-beta defensin
and anti-inflammatory properties,
could be valid in the search for novel
therapies and tools for the prevention

of recurrent skin infections in atopic
dermatitis patients. It is important
to note that this is an ongoing study
and as keratinocytes from more dogs
are tested, statistical significance for
different concentrations may change.
As this study was in-vitro, the next
step would be to test these extracts
on live atopic dermatitis models in
hopes of translating this potential
medicine to humans as a way to protect this vulnerable population from
skin infections.
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Bladder outlet obstruction (BOO) is a
pathological condition characterized
by increased bladder pressure and
decreased urine flow that may result
in the complete loss of bladder function.1 Pathological symptoms may
include abnormal thickening of the
detrusor muscles and may ultimately
result in the loss of bladder compliance and filling efficiency. There are
many causes of BOO, ranging from
spina bifida to prostate overgrowth,
making BOO a difficult condition
to treat.1
Currently, surgical correction
remains the most effective treatment
for BOO. However, replacement
tissues used are often transplanted
from the GI tract. This may result in
systemic acidosis and carcinogenesis
because acid secreting tissues were
accidentally incorporated into the
bladder.

BIOMEDICAL

FIGURE 1: Smoothelin isoform ratio of SKPs under different
conditions

A potential alternative solution
for this would be to use skin-derived
precursor cells (SKPs). SKPs are
easily accessible, pluripotent and
cost-effective. In order to determine the specificity of SKP differentiation, we performed PCR
analysis, using smoothelin gene as a
marker. There are two isoforms of
smoothelin; A and B. Smoothelin A is
expressed in bladder smooth muscle

cells while smoothelin B is expressed
mainly in vascular smooth muscle
cells. Interestingly, when SKPS are
cultured in conditioned media that
is not subjected to stress, there is a
high ratio of smoothelin A:B (Figure
1). This suggests that SKPs have the
potential to differentiate into bladder

BLADDER OBSTRUCTION
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smooth muscle cells in non-strained
conditions, making them an ideal
replacement tissue for BOO corrective surgery in the future.
Pharmacological treatment may
be another option for treating BOO.
Sirolimus (rapamycin), an immune
suppressant that showed remarkable
efficacy in treating stent stenosis
and other diseases characterized
by abnormal muscle proliferations.2
Current literature also suggests that
both vascular and bladder smooth
muscle cell proliferation requires
the mTOR pathway. Sirolimus,
an mTOR inhibitor, may be an
effective agent in preventing the
thickening of the bladder wall and
the eventual development of BOO.
I n or d e r to s i m u l a te t h e
obstructed bladder, rat bladder
smooth muscle cells were subjected
to hypoxia and stretch in vitro. As
expected, this resulted in a hypertrophic response and the cells became
thicker and much more numerous
(Figure 2). Smooth muscle actin
expression, a protein marker for the
level of differentiation in bladder
smooth muscles, also became significantly down-regulated in response to
both mechanical and hypoxic stress.
After sirolimus was added, the
hypertrophic response elicited by
hypoxia and stretch was prevented.
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FIGURE 2: Immunostaining of bladder smooth muscle cells treated with
and without rapamycin

Smooth muscle actin levels were
also maintained at a high level in the
sirolimus treated cells (Figure 2). This
indicates that bladder smooth muscle
cells maintained a differentiated and
therefore functional state. This is
important as much of the pathology
associated with BOO is due to the
improper contraction of the hypertrophic and de-differentiated bladder
smooth muscle wall. Ultimately,
Sirolimus administration may allow
the bladder to continue to contract
efficiently, even in the presence of
BOO inducing stressors like injury,

hypoxia and stretch. Consequently,
further studies in human cells are
needed for its potential to be fully
used.
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Reviews:
Underdiagnosed Pain in HIV/AIDS Patients
Bahaa Daoud,
MSIII

Human Immunodeficiency Virus
(HIV) is primarily a sexually transmitted disease that depresses the
body ’s immune system — specifically the depletion of CD4+
T-lymphocytes. Individuals with
CD4+ counts of <200 cells/μL are
defined as having Acquired Immune
Deficiency Syndrome (AIDS). In the
United States alone, there are approximately 1.1 million individuals living

with HIV/AIDS with an incidence
of 56,000 new infections each year.
Clinically, HIV/AIDS presents
with myriad symptoms, including
various cardiovascular diseases,
hepatobiliary diseases, renal diseases, or, most commonly, secondary
opportunistic infections. These
symptoms can often be controlled
with highly active anti-retroviral
therapy (HAART), which effectively
produces a state of chronic-treated
HIV/AIDS. Chronic persistence of
the virus may involve the central nervous system and lead to neurological
symptoms such as cognitive impairment, gait disorders and various pain
syndromes1.
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Though commonly occurring
and despite the importance of pain
management in chronic HIV, pain
syndromes continue to be underrecog n i zed a nd u nder treated.
Furthermore, clinicians seldom
explore HIV-associated pain syndromes2 . The most common pain
syndrome occurring in HIV/AIDS
patients is distal sensory polyneuropathy (DSP), which initially presents as paresthesias in the fingers and
toes in a “stocking and glove distribution.” Weeks later, it converts into a
burning and “knife-stabbing” pain3,4.
While the specific mechanisms of
DSP are still uncertain, many studies
have suggested that it is due to a combination of the virus, CNS immune
response, and specific treatments.
The envelope protein of the virus
(gp120), spinal cord glial cells (with
their respective chemokine receptors
CXCR4 and CXCR5) and nucleoside reverse transcriptase inhibitors
(NRTIs) may all be implicated in the
formation of DSP5. In brief, gp120
can increase prostaglandin E2 levels
and, through Kappa opioid pathways,
facilitate an increase in intracellular
calcium. This signals the mitochondrial to release reactive oxygen species (ROS) and nitric oxide (NO) and,
ultimately, leads to pain. Another
possible mechanism is through direct
or indirect (viral shedding in PNS)
activation of glial cells at their respective chemokine receptors. Once activated, they release pro-inflammatory
cytokines (TNFa, IL-1 and IL-6) that
directly promote increased neuronal
sensitivity to pain. NRTIs can exacerbate these effects by increasing the
number of CXCR4 receptors as well
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as directly increasing intracellular
calcium, leading to an enhanced pain
state (Figure 1).
HIV-related DSP appears to
be resistant to most first-line neuropathic pain pharmacotherapy 5 .
While many randomized controlled
trials (RCTs) of pharmacological
treatments for DSP have been performed, few demonstrate superiority
over the placebo. The most notable of
the group is the clinically available
high-dose topical capsaicin [NNT
6.46, 95% CI (3.86-19.69)]. Another
exception, although not recommended as routine, is smoked cannabis [NNT 3.38, 95% CI(1.38-4.10)].
Recombinant human nerve growth
factor (rhNGF) has shown promise
in a recent study but is not clinically
available6. Finally opioids, especially

chronic mu-receptor agonists, can be
used to treat DSP but some studies
have cautioned that they should only
be used on a short-term basis and only
when there are no alternatives due to
their potential pro-nociceptive properties in HIV-DSP patients5.
It needs to be emphasized that
DSP is one of the most significantly
underdiagnosed conditions in the
United States 4 . Coupled with the
lack of practical treatments available,
providers are failing to meet the pain
management needs of HIV/AIDS
patients. It is imperative to find new
treatment strategies for DSP in order
to further improve the quality of life
for HIV/AIDS patients.
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A Review of Neural Biochemical Markers for Mild
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In the United States, more than 1.5
million people experience traumatic
brain injury, of which approximately
75% sustain a mild traumatic brain
injury (mTBI)1. According to the
Centers for Disease Control and
Prevention, mTBIs — also known
as concussions — are caused by
blunt force trauma to the head with
one or more of the following symptoms: a period of altered mental
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status, impaired cognitive ability,
loss of consciousness lasting less
than 30 minutes, or observed signs
of neurological or neuropsychological dysfunction.1 Annual costs
for injuries related to mTBI total
nearly $17 billion 1. Growing concern about injuries involving motor
vehicle accidents, sports, and military
combat have spurred research for
mTBI1,2,3 . However, heterogeneity
of injuries and study designs have
made evaluation of mTBI inconsistent2; thus, there is a need to identify
effective biological markers in brain
injury to allow for standardization
in diagnostic criteria and qualities of
prognosis4. This review aims to consolidate and examine existing neural
biochemical markers that have been
considered as possible candidates

in the characterization of mTBI
for both diagnostic and prognostic
purposes.
A literature search was performed
using PubMed and MEDLIN E
databases, limited to the past 10
years. Further searches used MeSH
databases using key words mTBI,
serum biomarkers, and traumatic
brain injur y. Manual reviews of
articles collected were made, examining candidate markers for mTBI
with regards to their nature, effectiveness, and timing. Upon review
of the literature, glial fibrillar y
acidic protein-breakdown products
(GFA P-BDP) showed the most
promising results as a biological
marker for mTBI. GFAP-BDP was
detected within one hour post-mTBI,
and was associated with measures of
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More than 1.5 million Americans experience
traumatic brain injuries each year. Computed
tomography (CT) scans are most commonly
used soon after an injury to diagnose possible
life-threatening problems. Magnetic resonance
imaging (MRI) is used to identify signs of injury
such as minute bleeding, small areas of bruising,
or scarring that are invisible on a CT scan.

Heterogeneity of injuries and study designs have made
evaluation of mTBI inconsistent; thus, there is a need
to identify effective biological markers in brain injury
to allow for standardization in diagnostic criteria and
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qualities of prognosis.
injury severity as well as focal mass
lesions4. Ubiquitin carboxy-terminal
hydrolase (UCH-L1) and alpha-II
spectrin signature breakdown products (αII spectrin SBDP) require
further evaluation as viable markers
for mTBI, yet are more promising
than older researched markers such
as S100 protein beta-beta homodimer
isoform (S100β), cleaved tau protein
(CTP), and neuron specific enolase
(NSE), which all show conflicting
results and inconsistencies in published data3,4. The benefits remain
that the availability of a biochemical
marker panel for brain injury would
be similar to those seen in cardiac,
renal, and hepatic function panels
and, as such, neural markers play a
promising and necessary role in the
characterization of brain injury and
cost efficiency3.
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for mTBI to increase consistency and
credibility in data in contrast to previous independent studies that used
varying methodologies. Once a viable
neural biochemical marker has been
identified, a logical subsequent step
would be to consider development of
a protocol for evaluating the utility
of integration of neural biochemical
marker assays, neuroimaging studies
and neurocognitive assessments,
related to early diagnostic and prognostic indications for mTBI patients.
1.

This brief review demonstrates
the deficiency in research of neural
biomarkers for the evaluation of
mTBI 2,4 . Various research groups
have begun to reevaluate the older
biomarker candidates with improved
guidelines, especially S100β, and
research is ongoing for GFAP-BDP,
UCH-L1, and αII Spectrin SBDP
markers. There is a need to fully
identif y the pathophysiological
mechanisms of traumatic brain
injury in order to isolate candidate
protein markers for the detection
of injury severity and correlation.
It is anticipated that a viable neural
biochemical marker for mTBI will
be attainable especially with the
prospect of utilizing GFAP-BDP4 .
There is a need for longitudinal and
standardized comparison testing
between all promising neural markers
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The incidence and hospitalizations
due to skin and soft tissue infections
(SSTIs) has steadily increased over
the last decade primarily due to the
emergence of community acquired
methicillin resistant Staphylococcus
aureus (CA-MRSA)1,2 . The emergency department (ED) is a common
site for SSTI treatment and serves
populations not diagnosed by traditional surveillance, including the
homeless and uninsured. However,
the use of near real-time syndromic
surveillance within the ED for monitoring local epidemiologic trends in
SSTI presentation where laboratory
data is unavailable has not been
previously described. Our study
sought to describe the epidemiology
of ED visits for SSTIs in an urban
setting with diverse neighborhood
populations using Boston Public
Health Commission’s Syndromic
Surveillance System data from 2007
to 2011. The aims of the study were:
to demonstrate the use of syndromic
surveillance data for tracking the
patterns of SSTIs in an urban population; to estimate the burden of ED
visits associated with SSTIs; and
to determine potential geographic
hotspots for SSTIs.
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Final diagnosis International
Classification of Diseases (ICD-9
CM) codes for SSTIs, as well as chief
complaints with SSTI-associated
words (i.e. abscess, cellulitis), were
used to define SSTI-related ED
visits. Identified SSTI visits were
then mapped to one of 16 Boston
neighborhoods, each having a unique
demographic profile with differences
in race, socioeconomic status, age,
and population density 3 . Trends
within patient demographics were
examined inside potential hotspots
of neighborhood clustering for SSTI
visits in EDs.
We estimated unique SSTI visits
to represent 3.29% (n=45,252) of all
visits to Boston EDs from 2007 to
2011. During the given time frame,
the overall yearly percentage of
SSTI visits increased from 3.08% to
3.51%. Additionally, we observed a
seasonal pattern with the peak incidence of SSTI visits occurring in the
summer. The majority of SSTI visits
(54%) were among patients 18–44
years old 4. More specifically, males
accounted for less than half of all
ED visits for each year of the study
but accounted for 52% of total SSTI
visits. Although accounting for only
24% of Boston’s population,4 African
American patients accounted for a
disproportionate 43% of total SSTI
visits. Furthermore, the five-year
average rate of SSTI visits for black
patients (281.2 per 10,000) was 2.8
times greater [CI 2.7-3.0] than the
rate for Caucasian patients (99.0
per 10,000). Overall, the five-year
average percent of neighborhoodspecific ED visits for SSTIs had a

geographic distribution ranging from
a low of 2.69% to a high of 4.11%.
Our study demonstrates the use of
syndromic surveillance to track the
epidemiology of community acquired
SSTIs through the use of disposition data. Our results emphasize the
significant burden of SSTIs in this
urban population, accounting for up
to 4% of all ED visits. Additionally,
our syndromic surveillance methods
may be useful in providing information regarding the local epidemiology
of SSTIs, including the identification
of neighborhood hotspots. Local
syndromic sur veillance systems
have the potential to provide public
health authorities and ED clinicians
near real-time data on trends in
demographic risk factors despite an
unavailability of laboratory data.
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with one-month history of a brown
nodule in the inferotemporal aspect
of his left eye (Figure A). Iris nevus
was diagnosed and the patient was
observed. Nearly two years later the
lesion had grown in basal diameter
and thickness (Figure B, C, D), and

the tumor was excised by partial
lamellar scleral flap and sector iridectomy (Figure E). Histopathology
confirmed spindle cell iris melanoma.

IRIS MELANOMA
Continued on p. 30
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Iris melanoma is a rare condition,
comprising 4% of uveal melanoma
and having a prevalence of 5.1 cases
per million population in the United
States1. The mean age of presentation
is 40–47 years, which is approximately
10-20 years younger than patients
with other uveal melanomas2. Most
patients are Caucasian (97.8%) with
blue or green irides (97%), and males
and females are affected equally 1,3 .
Pediatric (younger than 21 years
of age) iris melanoma is especially
rare, representing only 8% of iris
melanoma cases1. The differential
diagnosis of iris melanoma includes
primary iris cyst (38%), iris nevus
(31%), essential iris atrophy (5.7%),
iris foreign body (4.5%), peripheral
anterior synechiae (2.5%), and iris
metastasis (2.5%)4. Iris melanoma in
children is characterized by smaller
tumors, less seeding, and fewer cases
of secondary glaucoma compared to
adults1.
This report presents a case of
pediatric iris melanoma to demonstrate the unavoidable possibility of
recurrence and complications associated with iris melanoma in children
despite standard treatment protocols
and proper surgical technique. A
15-year old Caucasian male presented

CASE REPORT

FIGURE 1: A 15-year-old Caucasian male with a pigmented iris lesion. The
iris lesion was small at presentation (A) and showed growth over 2 years
(B) visible on gonioscopy (C) and anterior segment optical coherence
tomography (D). The lesion was excised by partial lamellar scleral flap
and sector iridectomy (E). Later tumor recurrence in the anterior chamber
angle with elevated intraocular pressure necessitated Iodine125 plaque
radiotherapy (F).
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IRIS MELANOMA
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Two years post-operatively, tumor
recurrence with anterior chamber
angle involvement and secondary
glaucoma developed. The presence of glaucoma in eyes with iris
melanoma complicates treatment.
Iris melanoma associated with glaucoma (compared to iris melanoma
without glaucoma) is more likely to
be thicker, involve the angle, and

to 9% of reported cases3. Older age,
involvement of the anterior angle,
elevated IOP, and extraocular extension are all risk factors for metastasis1.
Resection and plaque radiotherapy
for iris melanoma have remarkable
local success rates but complications
of therapy can lead to visual damage.
Visual damage will be an unavoidable
complication in this case but treatments such as
plaque radiotherapy need
to be implicated in cases
such as this to
ensure tumor
eradication
and preservation of l ife.
This case
r e p or t o utlines current
management options for pediatric
iris melanoma and also demonstrates
the possibility of tumor recurrence
that persists despite proper initial
surgical management. This report
and further studies on ocular melanoma treatment and recurrence will
serve as invaluable assets to improve
treatment options with the goal of
preventing recurrence and minimizing treatment complications.
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This case report outlines current management
options for pediatric iris melanoma and
also demonstrates the possibility of tumor

recurrence that persists despite proper initial
surgical management.
demonstrate iris stromal seeding.5
The patient was then treated with
custom designed Iodine1,2,5 plaque
radiotherapy (Figure F). Local tumor
recurrence after resection in patients
with iris melanoma ranges from 2%
to 14%, depending on surgeon and
surgical technique. The median time
from resection to recurrence is 45
months.3 Metastasis after local iris
melanoma resection occurs in 0%
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Although the average age of first-year
medical students is 24, an increasing
number of mature-age students,
defined as those over age 30, are
entering medical school. Most studies
of mature-age medical students have
examined academic performance
using quantitative research design.1 ,
2
Few studies have employed qualitative methodology to determine the
experience of mature-age medical
students, especially in the clinical
setting.
To further study this, a recruitment email was sent to all medical
students enrolled in clinical rotations. First responders were interviewed until saturation in emerging
themes was achieved. Interviews
were conducted and recorded in
a private office setting, then transcribed. Five mature-age students

MEDICAL EDUCATION

and four traditional students were
interviewed. Using methodology
for qualitative research described by
Mustakas (1994), the investigators
individually coded the transcripts to
identify emerging themes.3 Coded
themes underwent peer review, with
triangulation of data
collection, to determine the main themes.
Three main themes
emerged f rom the
study. First, abundant
life experience influences students’ perception of their role
on clinical rotations.
A mature-age student
explained, “Having
kids, being married
and divorced, helps
in connecting with
patients.” Previous
work experience shapes expectations
as a physician-in-training.
While traditional students tend to
be intimidated, mature-age students
desire to take initiative. Age plays a
role in the students’ ability to relate to
senior team members, as well as medical school colleagues. Traditional
students note that mature-age students are “more realistic” due to their
“life experience in the workplace.”
Mature-age students draw upon previous life experiences, which shapes

role expectations, as well as medical
team dynamics. These differences
may have implications in training the
growing number of mature-age medical students. A larger scale qualitative study including multiple medical
school sites is being developed.

A mature-age student explained,
“Having kids, being married and
divorced, helps in connec ting
with patient s.” Previous work
experience shapes expectations as a
physician-in-training.
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